1-866-598-7166

A Study to Test Different Combination Immunotherapy Treatments in Patients with Advanced Kidney Cancer (FRACTION-RCC)

Trial ID: NCT02996110
Kidney Cancer Type: Clear Cell


Background:

Ipilimumab (Yervoy®) and Nivolumab (Opdivo®) are immunotherapy drugs that work by reactivating the body’s immune response to target and destroy cancer cells. The combination of these drugs is a Health Canada-approved treatment for patients with advanced kidney cancer.

In this trial, researchers will combine Nivolumab with several experimental immunotherapy drugs to see if they are more effective than Ipilimumab in combination.

  • Relatlimab –  Targets a new anti-cancer target called LAG-3
  • BMS-986205 – Targets a new anti-cancer target called IDO1
  • BMS-813160 – Targets a new anti-cancer target called CCR2/5

 

The Trial:

This study will investigate the safety and effectiveness of Nivolumab in combination with four other immunotherapy drugs.

Accordingly, you may be randomly enrolled on any one of four treatment groups:

  • Nivolumab + Ipilimumab
  • Nivolumab + Relatlimab
  • Nivolumab + BMS-986205
  • Nivolumab + BMS-813160


Basic Eligibility:

  • Clear cell kidney cancer
  • Cancer has spread or cannot be removed by surgery

Additional eligibility criteria will apply. Please speak to your doctor.

 

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreR.S. McLaughlin Durham Regional Cancer Centre Principal Investigator LocationOshawa, ON Trial StatusRecruiting
Hospital / Cancer CentrePrincess Margaret Centre | University Health Network Principal InvestigatorDr Srikala Sridhar LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentreJuravinski Cancer Centre | Hamilton Health Sciences Centre Principal InvestigatorDr Sebastian Hotte LocationHamilton, ON Trial StatusRecruiting
Hospital / Cancer CentreHôpital général juif | Jewish General Hospital Principal InvestigatorDr Wilson H. Miller Jr LocationMontréal, QC Trial StatusRecruiting
Hospital / Cancer CentreHôpital Hôtel-Dieu de Québec - CHUQ Principal InvestigatorDr Vincent Fradet LocationQuébec, QC Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!